641 related articles for article (PubMed ID: 29948047)
21. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study.
Bang WJ; Oh CY; Yoo C; Cho JS; Yang DY; Lee DH; Lee SH; Chung BH
Int J Impot Res; 2013; 25(4):149-54. PubMed ID: 23303333
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
Sun K; Sun F; Yao H; Zhang D; Wu G; Wang T; Wang J; Wu J
Am J Mens Health; 2020; 14(6):1557988320980180. PubMed ID: 33342335
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis.
Qiangzhao L; Xiaofeng Z; Fenghai Z; Qiong L; Fa Z; Bohong G; Xinsheng X
Medicine (Baltimore); 2020 Oct; 99(43):e22834. PubMed ID: 33120811
[TBL] [Abstract][Full Text] [Related]
24. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
25. To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia: A protocol for systematic review and meta analysis.
Ma C; Zhang J; Cai Z; Li H
Medicine (Baltimore); 2020 Jan; 99(3):e18712. PubMed ID: 32011446
[TBL] [Abstract][Full Text] [Related]
26. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta-analysis of urodynamic studies.
Fusco F; Creta M; De Nunzio C; Gacci M; Li Marzi V; Finazzi Agrò E
Neurourol Urodyn; 2018 Aug; 37(6):1865-1874. PubMed ID: 29603785
[TBL] [Abstract][Full Text] [Related]
27. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
Xu Z; Jia RP
Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
[TBL] [Abstract][Full Text] [Related]
28. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis.
Wang Y; Bao Y; Liu J; Duan L; Cui Y
Low Urin Tract Symptoms; 2018 Jan; 10(1):84-92. PubMed ID: 29341503
[TBL] [Abstract][Full Text] [Related]
29. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs.
Sun X; Guan W; Liu H; Tang K; Yan L; Zhang Y; Zeng J; Chen Z; Xu H; Ye Z
BMC Urol; 2018 May; 18(1):30. PubMed ID: 29724204
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
[TBL] [Abstract][Full Text] [Related]
32. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
33. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Miller MS
Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
[TBL] [Abstract][Full Text] [Related]
34. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
35. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
De Nunzio C; Presicce F; Tubaro A
Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
[TBL] [Abstract][Full Text] [Related]
36. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of an α
Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
[TBL] [Abstract][Full Text] [Related]
38. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
[TBL] [Abstract][Full Text] [Related]
39. Medical therapy for benign prostatic hyperplasia: a review.
Van Asseldonk B; Barkin J; Elterman DS
Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
